Moderna prepares to launch Covid vaccine : Ships first consignment to US for researchers


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ Moderna prepares to launch Covid vaccine : Ships first consignment to US for researchers
It took only 6 weeks for biotech major to develop the mRNA based covid vaccine

US biotech firm Moderna has shipped an experimental coronavirus vaccine to US government researchers just six weeks after it started working on the immunization. Initial trials of the potential vaccine could begin in April, but the process of testing and approvals would last at least a year.

Moderna (MRNA) said in a statement Monday that the first batch of its novel coronavirus vaccine, called mRNA-1273, has been sent to the National Institute of Allergy and Infectious Diseases (NIAID). Moderna said the first vials of the experimental vaccine would be used in a planned Phase 1 study in the United States, which typically involves testing a vaccine on a small number of healthy humans.NIAID Director Anthony Fauci said that a clinical trial could start by the end of April, the "first step" in potentially making a vaccine available for use.

The Wall Street Journal, which was first to report the development, said that two doses of the vaccine would be tested on volunteers to see if it produces an immune response that protects against the virus. Fauci told CNN that 45 people would participate in the trial. Even if the clinical trial is successful, further testing and regulatory approvals would be needed before the vaccine could be deployed widely.

Health officials and pharmaceutical companies around the world are working at a breakneck pace to identify treatments or a vaccine to help fight the coronavirus, which has infected more than 80,000 people around the world.

Fauci previously told CNN that researchers could expedite the approval process for a vaccine following a successful Phase 1 trial in an attempt to halt the spread of the virus.


But even when proceeding at an "emergency speed," a vaccine would not be available for use for at least a year or 18 months, he said Tuesday. Moderna is not the only drug company hoping to find an immunization for the virus.
Pharma giants Johnson & Johnson (JNJ) and GlaxoSmithKline (GLAXF) are working on vaccines, as are government scientists including some at NIAID.

While the experimental vaccine developed by Moderna remains unproven, the speed at which it was created represents a breakthrough. According to Moderna, the vaccine was developed within 42 days of the company obtaining genetic information on the coronavirus. By comparison, it took researchers about 20 months to start human tests of the vaccine for SARS, an older coronavirus, according to a journal paper written by Fauci.

Tags : #Moderna #MrnaCovidVaccine #GlaxoSmithkline #NIAID #WallStreetJournal #JohnsonAndJohnson #LatestCovidVaccineNewsOct31

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-



Trending Now

CARE Hospitals to Offer Free Vascular Health Check on National Vascular DayAugust 05, 2026
Breastfeeding Myths That New Mothers Should Stop BelievingAugust 05, 2026
Why Modern Lifestyle Causes Chronic InflammationAugust 05, 2026
Endometriosis Awareness: Understanding the Silent Condition Affecting Millions of Indian WomenAugust 05, 2026
A Complete Guide to Pregnancy Health Tips for Indian Women: Nutrition, Wellness, and What Every Expectant Mother Should KnowAugust 05, 2026
Metropolis Healthcare reports strong Q1FY27 performance, with revenue up 17% to ₹450 crore and EBITDA up 27% YoYAugust 04, 2026
India's Silent Liver Health Crisis: New Data Points to Urgent Need for Screening and PreventionAugust 04, 2026
Eureka Forbes Launches 'Ghar Ka New Favourite' Campaign showcasing Forbes SmartClean Robotic Vacuum Cleaner with Shraddha KapoorAugust 04, 2026
Why Preventive Healthcare for Children Is One of the Most Important Investments India Can MakeAugust 04, 2026
The Role of Pathology in Healthcare: From Diagnosis to Disease PreventionAugust 04, 2026
Pathophysiology of Psoriatic Arthritis: Clinical Presentation, Joint Damage Mitigation, and BiologicsAugust 04, 2026
Comprehensive Evaluation of Syncope: Cardiac vs. Neurological Origin WorkupsAugust 04, 2026
Common Medical Terms Explained: A Plain-Language Guide for Indian Patients and Healthcare SeekersAugust 03, 2026
Why Radiology Is the Backbone of Modern Medical Diagnosis and TreatmentAugust 03, 2026
Managing Urban Stress: Science-Backed Strategies for Mental Resilience in 2026 August 01, 2026
Managing Chronic Inflammation: The Role of Anti-Inflammatory Indian SuperfoodsAugust 01, 2026
Pathophysiology of Psoriatic Arthritis: Clinical Presentation, Joint Damage Mitigation, and BiologicsAugust 01, 2026
Early Markers of Glaucoma: Structural vs. Functional Ophthalmic Diagnostic ProtocolsAugust 01, 2026
Managing Complex Diabetic Foot Ulcers: Multidisciplinary Wound Care, Offloading, and RevascularizationAugust 01, 2026
The Future of Preventive Medicine: How India Is Moving From Cure to PreventionAugust 01, 2026